REG - Oxford Biomedica PLC - Result of Annual General Meeting

Oxford BioMedicaAnnouncement

Wed 18:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250611:nRSK4780Ma&default-theme=true

RNS Number : 4780M  Oxford Biomedica PLC  11 June 2025

 

OXB

Result of Annual General Meeting and Confirmation of Board Changes

 

Oxford, UK - 11 June 2025: OXB (LSE: OXB) (the "Company"), a global quality
and innovation-led cell and gene therapy CDMO, today announces that all
proposed resolutions were duly passed at its Annual General Meeting ("AGM"),
held at 3 pm on 11 June 2025 in Oxford. As proposed in the Notice of AGM, all
resolutions were decided by poll vote.

 

The full text of all the resolutions can be viewed in the Notice of AGM by
visiting the Company's website at www.oxb.com (http://www.oxb.com/)

 

Copies of the document setting out the above resolutions passed at the 2025
AGM have been submitted to the National Storage Mechanism and will shortly be
available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

 

On the Record Date (9 June 2025) there were 106,127,365 ordinary shares of 50
pence each in issue, each carrying one vote per share.

 

Further to the announcement by the Company on 9 April 2025, Stuart Henderson
has stepped down from the Company's Board of Directors (the "Board") with
immediate effect following the conclusion of today's AGM.

 

Following Stuart Henderson's departure, Colin Bond, who joined the Board as an
Independent Non-Executive Director in January 2025, will succeed Mr. Henderson
as Audit Committee Chair and Peter Soelkner, who joined the Board as an
Independent Non-Executive Director in March 2024, will assume the position of
Vice Chair. These changes are effective immediately.

 

                                                                                       Votes For (incl. votes at the Chair's discretion)                    Votes Against                           Votes Withheld*                 Total votes cast**  Result

                                                                                                                                          % of votes cast                         % of votes cast

      Resolutions
      Ordinary resolutions
 1    To receive and adopt the Company's Annual Report and accounts for the             78,099,206                                        99.99%                    4,993         0.01%
      financial year ended 31 December 2024, the Directors' Report, and the Report

      of the Independent Auditors on those accounts and reports.

                                                                                                                                                                                                                                                        PASS

                                                                                                                                                                                                    247,911                         78,104,199
 2    To receive the Directors' Remuneration Report and the Report of the               71,581,194                                        91.65%             6,517,342            8.35%
      Independent Auditors on the auditable part of the Remuneration Report

      (excluding the Directors' Remuneration Policy) for the financial year ended 31                                                                                                                                                                    PASS
      December 2024.

                                                                                                                                                                                                    253,574                         78,098,536
 3    To appoint Colin Bond as a Director of the Company.                               78,094,045                                        99.98%                  15,037          0.02%                         243,028              78,109,082         PASS
 4    To appoint Dr. Lucinda Crabtree as a Director of the Company.                     78,099,379                                        99.99%                    9,573         0.01%                         243,158              78,108,952         PASS
 5    To appoint Laurene Espinasse as a Director of the Company.                        78,091,686                                        99.98%                  17,593          0.02%                         242,831              78,109,279         PASS
 6    To reappoint Dr. Roch Doliveux as a Director of the Company.                      77,646,951                                        99.42%                453,708           0.58%                         251,451              78,100,659         PASS
 7    To reappoint Professor Dame Kay Davies as a Director of the Company.              77,659,388                                        99.42%                450,237           0.58%                                                                 PASS

                                                                                                                                                                                                    242,485                         78,109,625
 8    To reappoint Dr. Frank Mathias as a Director of the Company.                      77,592,469                                        99.34%                513,155           0.66%                                                                 PASS

                                                                                                                                                                                                    246,486                         78,105,624
 9    To reappoint Robert Ghenchev as a Director of the Company.                        78,087,996                                        99.98%            15,604                0.02%                                                                 PASS

                                                                                                                                                                                                    248,510                         78,103,600
 10   To reappoint Namrata Patel as a Director of the Company.                          78,088,438                                        99.98%                  19,162          0.02%                         244,510              78,107,600         PASS
 11   To reappoint Dr. Heather Preston as a Director of the Company.                    77,160,176                                        98.78%                949,193           1.22%                         242,741              78,109,369         PASS

 12   To reappoint Peter Soelkner as a Director of the Company.                         77,682,985                                        99.46%                420,357           0.54%                         248,768              78,103,342         PASS
 13   To appoint PricewaterhouseCoopers LLP as auditors of the Company from the         78,091,769                                        99.98%                  12,197          0.02%                                                                 PASS
      conclusion of the 2025 AGM until the conclusion of the next AGM of the Company

      at which the accounts are laid.

                                                                                                                                                                                                    248,144                         78,103,966
 14   To authorise the Audit Committee for and on behalf of the Board to determine      78,093,125                                        99.99%                    6,387         0.01%                                                                 PASS
      the auditor's remuneration.

                                                                                                                                                                                                    252,598                         78,099,512
 15   To authorise the Directors to allot shares.                                       78,082,788                                        99.97%                  20,326          0.03%                         248,996              78,103,114         PASS
      Special resolutions
 16   To authorise the Directors to disapply pre-emption rights.                        78,024,010                                        99.90%                  76,292          0.10%                         251,808              78,100,302         PASS
 17   To authorise the Directors to further disapply pre-emption rights for             78,021,831                                        99.89%                  82,729          0.11%                                                                 PASS
      acquisitions and specified capital investments.

                                                                                                                                                                                                    247,550                         78,104,560
 18   To amend the Articles by deleting the existing articles 43.2 and 43.4G and        78,024,468                                        99.91%                  72,785          0.09%                                                                 PASS
      replacing them with new articles 43.2 and 43.4G respectively.

                                                                                                                                                                                                    254,857                         78,097,253
 19   To permit the Directors to convene general meetings (other than annual general    78,052,385                                        99.92%                  59,729          0.08%                                                                 PASS
      meetings) on not less than 14 days' notice.

                                                                                                                                                                                                    239,996                         78,112,114

* A vote withheld is not a vote in law and is not counted towards votes cast
in respect of a resolution.

 

-Ends-

 

Enquiries:

OXB:

Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com
(mailto:cosec@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), a dual-plasmid system for AAV production, suspension
and perfusion process using process enhancers and stable producer and
packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGPKDBPABKDFAD